Login to Your Account

Blueprint drawing $25M for kinase inhibitors bid

By Randy Osborne
Staff Writer

Thursday, January 9, 2014
In its attempt to “replicate the Gleevec story in other tumor types,” Blueprint Medicines Inc.’s Series B round brought in $25 million that will fund the push led by “an elite group of people who have specialized in developing selective kinase inhibitors to known or very clear genomic drivers of cancers,” said Kyle Kuvalanka, chief business officer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription